{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:45:51Z","timestamp":1793148351822,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Key R&D Program of Zhejiang Province Science and Technology Plan","award":["2023C03032"],"award-info":[{"award-number":["2023C03032"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate the long-term effectiveness and safety of baricitinib (BAR) add-on therapy for refractory or severe juvenile dermatomyositis (rsJDM) in a practical, real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-centre retrospective study, 27 children with rsJDM and poor response to corticosteroids (CS) and immunosuppressants were treated with BAR. Disease activity was assessed via physician global assessment of overall disease activity (PhyGloVAS), the childhood myositis assessment scale (CMAS), manual muscle testing-8 (MMT-8) and the disease activity score (DAS). Disease response was determined according to the PRINTO criteria at 0, 6, 12, 24 and 36\u2009months after the initiation of BAR treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over an average follow-up period of 25.1\u2009months (ranging from 12 to 58\u2009months), 77% of patients (21 out of 27) experienced improvement in skin rashes, with complete resolution in 62% of patients. Analysis of the median values revealed a significant decrease in the DAS of the skin at 12\u2009months (6.0 vs 0.8, P &amp;lt; 0.01). Furthermore, the CMAS score significantly increased at 12\u2009months (40.5 [30.8, 45.0] vs 52.0 [50.0, 52.0], P &amp;lt; 0.05), and the MMT-8 score also notably increased at 12\u2009months (66.0 [47.8, 72.3] vs 79.0 [79.0, 80.0], P = 0.004) Last observation for the three patients who did not respond was carried forward for their month 12 data. Over the course of the 36-month follow-up, a total of 70% of patients (19 out of 27) achieved inactive disease inactive disease (ID), with a reduction in CS dosage from baseline (0.50 [0.34, 0.89] mg\/kg\/day) to (0 [0, 0.10] mg\/kg\/day) at 36\u2009months (P &amp;lt; 0.001). One-third of patients (9 out of 27) discontinued CS treatment. The percentage of patients who achieved ID was 48.1% (13\/27), 70.8% (17\/24), 90.0% (18\/20) and 92.3% (12\/13) at the 6-, 12-, 24- and 36-month observation points, respectively. Radiographic analysis revealed an improvement in calcinosis in one patient, while stabilization was observed in two others. Interstitial lung disease improved in three patients and stabilized in three others. Macrophage activation syndrome was resolved in two patients. One patient required hospitalization and temporary cessation of BAR due to herpes zoster virus infection. There were no deaths or anyone who had to permanently discontinue baricitinib due to an adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrated the general long-term effectiveness and safety of BAR treatment in patients with rsJDM over a follow-up period of 36\u2009months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf225","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T19:29:39Z","timestamp":1746041379000},"page":"4948-4956","source":"Crossref","is-referenced-by-count":11,"title":["Long-term effectiveness and safety of baricitinib treatment on refractory or severe juvenile dermatomyositis"],"prefix":"10.1093","volume":"64","author":[{"given":"Zhaoling","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuTao","family":"Lu","sequence":"additional","affiliation":[{"name":"Advanced Institute of Information Technology (AIIT), Peking University , Hangzhou,","place":["China"]},{"name":"College of Computing, Georgia Institute of Technology , Atlanta, GA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiSheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-868X","authenticated-orcid":false,"given":"Li","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-9493","authenticated-orcid":false,"given":"Meiping","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"2025090315124084300_keaf225-B1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nature Rev Rheumatol"},{"key":"2025090315124084300_keaf225-B2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken, N.J.)"},{"key":"2025090315124084300_keaf225-B3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/art.40328","article-title":"Myogenic progenitor cells exhibit type I interferon-driven proangiogenic properties and molecular signature during juvenile dermatomyositis","volume":"70","author":"Gitiaux","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken, N.J.)"},{"key":"2025090315124084300_keaf225-B4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","article-title":"Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers","volume":"86","author":"Min","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025090315124084300_keaf225-B5","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/rheumatology\/keaa657","article-title":"Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?","volume":"60","author":"Heinen","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025090315124084300_keaf225-B6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (jak) inhibition with baricitinib in refractory juvenile dermatomyositis","volume":"80","author":"Kim","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025090315124084300_keaf225-B7","doi-asserted-by":"crossref","first-page":"962585","DOI":"10.3389\/fped.2022.962585","article-title":"Short-term effectiveness of baricitinib in children with refractory and\/or severe","volume":"10","author":"Wang","year":"2022","journal-title":"Front Pediatr"},{"key":"2025090315124084300_keaf225-B8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2025090315124084300_keaf225-B9","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090315124084300_keaf225-B10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2025090315124084300_keaf225-B11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheumatism"},{"key":"2025090315124084300_keaf225-B12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/acr2.11493","article-title":"Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis","volume":"4","author":"Oddis","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2025090315124084300_keaf225-B13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12969-018-0257-6","article-title":"Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria","volume":"16","author":"Hinze","year":"2018","journal-title":"Pediatric Rheumatol Online J"},{"key":"2025090315124084300_keaf225-B14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.bor.0000179949.65895.53","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"17","author":"Fathi","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"2025090315124084300_keaf225-B15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/14397595.2016.1231102","article-title":"Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis","volume":"27","author":"Sato","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2025090315124084300_keaf225-B16","first-page":"S118","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient\/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)\/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (DAS), short form 36 (sf-36), child health questionnaire (CHQ), physician global damage, myositis damage index (mdi), quantitative muscle testing (QMT), myositis functional index-2 (FI-2), myositis activities profile (map), inclusion body myositis functional rating scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality index (DLQI)","volume":"63","author":"Rider","year":"2011","journal-title":"Arthrit Care Res"},{"key":"2025090315124084300_keaf225-B17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The Printo criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025090315124084300_keaf225-B18","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain J Neurol"},{"key":"2025090315124084300_keaf225-B19","doi-asserted-by":"crossref","first-page":"102533","DOI":"10.1016\/j.autrev.2020.102533","article-title":"Calcinosis biomarkers in adult and juvenile dermatomyositis","volume":"19","author":"Chung","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025090315124084300_keaf225-B20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard-2022-223469","article-title":"Role of cd14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis","volume":"82","author":"Wilkinson","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025090315124084300_keaf225-B21","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1038\/s41467-024-49460-1","article-title":"Ifn\u03b3 causes mitochondrial dysfunction and oxidative stress in myositis","volume":"15","author":"Abad","year":"2024","journal-title":"Nat Commun"},{"key":"2025090315124084300_keaf225-B22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the janus-kinase inhibitor tofacitinib\u2014a report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J Autoimmun"},{"key":"2025090315124084300_keaf225-B23","doi-asserted-by":"crossref","first-page":"e387-8","DOI":"10.1093\/rheumatology\/keab421","article-title":"Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series","volume":"60","author":"Shneyderman","year":"2021","journal-title":"Rheumatology"},{"key":"2025090315124084300_keaf225-B24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12969-021-00637-8","article-title":"Jak inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology","volume":"19","author":"Ll Wilkinson","year":"2021","journal-title":"Pediatric Rheumatol Online J"},{"key":"2025090315124084300_keaf225-B25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib","volume":"19","author":"Peng","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2025090315124084300_keaf225-B26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","article-title":"Long-term follow-up of janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis","volume":"62","author":"Huang","year":"2023","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025090315124084300_keaf225-B27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with jak inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol (Hoboken, N.J.)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf225\/63049045\/keaf225.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/4948\/63049045\/keaf225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/4948\/63049045\/keaf225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:12:51Z","timestamp":1756926771000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/9\/4948\/8124374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,3]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf225","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,3]]}}}